Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer
The 5-year survival rate for ovarian cancer has remained relatively static over the past number of years, which can be attributed in part to the lack of new therapeutic strategies to target this disease. Although numerous other cancer types have benefited from the success of immune checkpoint inhibi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-10-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024149195 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846170266488537088 |
|---|---|
| author | A.E. Connor P.M. Lyons A.M. Kilgallon J.C. Simpson A.S. Perry J. Lysaght |
| author_facet | A.E. Connor P.M. Lyons A.M. Kilgallon J.C. Simpson A.S. Perry J. Lysaght |
| author_sort | A.E. Connor |
| collection | DOAJ |
| description | The 5-year survival rate for ovarian cancer has remained relatively static over the past number of years, which can be attributed in part to the lack of new therapeutic strategies to target this disease. Although numerous other cancer types have benefited from the success of immune checkpoint inhibitors, their use in clinical trials targeting ovarian cancer has shown limited efficacy. Most clinical trials have focused on PD-1/PD-L1 immune checkpoint blockade, either as a monotherapy or in combination with chemotherapies, however inhibiting other pathways may potentially be more efficacious in treating ovarian cancer. For example, drugs targeting some emerging immune checkpoints (such as LAG-3, TIM-3, TIGIT and PVRIG), are entering into clinical trials, which could show improved success for ovarian cancer patients. Similarly, predictive biomarkers that have been approved for use with immune checkpoint inhibitors, such as PD-L1 expression, are limited, as only the presence or absence of PD-L1 is assessed. However, the development of next generation predictive biomarkers, which assesses density and location of tumour infiltrating lymphocytes, could be more beneficial for this heterogenous cancer. In this review we discuss the use of immune checkpoint inhibitors in ovarian cancer, with a focus on high-grade serous disease, and delve into what the future may hold for immunotherapy in this cancer type. |
| format | Article |
| id | doaj-art-d7329195a1bc46559218c1ab097a87f6 |
| institution | Kabale University |
| issn | 2405-8440 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj-art-d7329195a1bc46559218c1ab097a87f62024-11-12T05:19:24ZengElsevierHeliyon2405-84402024-10-011020e38888Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancerA.E. Connor0P.M. Lyons1A.M. Kilgallon2J.C. Simpson3A.S. Perry4J. Lysaght5UCD School of Biology and Environmental Science, University College Dublin, Dublin, Ireland; UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland; Cell Screening Laboratory, University College Dublin, Dublin, Ireland; Corresponding author. School of Biology and Environmental Science, O'Brien Science Centre, UCD, Belfield, Dublin, 4, Ireland.Cancer Immunology and Immunotherapy Group, Department of Surgery, School of Medicine, Trinity Translational Medicine Institute and Trinity St. James's Cancer Institute, Trinity College Dublin, Dublin, IrelandCancer Immunology and Immunotherapy Group, Department of Surgery, School of Medicine, Trinity Translational Medicine Institute and Trinity St. James's Cancer Institute, Trinity College Dublin, Dublin, IrelandUCD School of Biology and Environmental Science, University College Dublin, Dublin, Ireland; UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland; Cell Screening Laboratory, University College Dublin, Dublin, IrelandUCD School of Biology and Environmental Science, University College Dublin, Dublin, Ireland; UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, IrelandCancer Immunology and Immunotherapy Group, Department of Surgery, School of Medicine, Trinity Translational Medicine Institute and Trinity St. James's Cancer Institute, Trinity College Dublin, Dublin, IrelandThe 5-year survival rate for ovarian cancer has remained relatively static over the past number of years, which can be attributed in part to the lack of new therapeutic strategies to target this disease. Although numerous other cancer types have benefited from the success of immune checkpoint inhibitors, their use in clinical trials targeting ovarian cancer has shown limited efficacy. Most clinical trials have focused on PD-1/PD-L1 immune checkpoint blockade, either as a monotherapy or in combination with chemotherapies, however inhibiting other pathways may potentially be more efficacious in treating ovarian cancer. For example, drugs targeting some emerging immune checkpoints (such as LAG-3, TIM-3, TIGIT and PVRIG), are entering into clinical trials, which could show improved success for ovarian cancer patients. Similarly, predictive biomarkers that have been approved for use with immune checkpoint inhibitors, such as PD-L1 expression, are limited, as only the presence or absence of PD-L1 is assessed. However, the development of next generation predictive biomarkers, which assesses density and location of tumour infiltrating lymphocytes, could be more beneficial for this heterogenous cancer. In this review we discuss the use of immune checkpoint inhibitors in ovarian cancer, with a focus on high-grade serous disease, and delve into what the future may hold for immunotherapy in this cancer type.http://www.sciencedirect.com/science/article/pii/S2405844024149195High-grade serous ovarian cancerImmune checkpoint inhibitorsTumour microenvironment |
| spellingShingle | A.E. Connor P.M. Lyons A.M. Kilgallon J.C. Simpson A.S. Perry J. Lysaght Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer Heliyon High-grade serous ovarian cancer Immune checkpoint inhibitors Tumour microenvironment |
| title | Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer |
| title_full | Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer |
| title_fullStr | Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer |
| title_full_unstemmed | Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer |
| title_short | Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer |
| title_sort | examining the evidence for immune checkpoint therapy in high grade serous ovarian cancer |
| topic | High-grade serous ovarian cancer Immune checkpoint inhibitors Tumour microenvironment |
| url | http://www.sciencedirect.com/science/article/pii/S2405844024149195 |
| work_keys_str_mv | AT aeconnor examiningtheevidenceforimmunecheckpointtherapyinhighgradeserousovariancancer AT pmlyons examiningtheevidenceforimmunecheckpointtherapyinhighgradeserousovariancancer AT amkilgallon examiningtheevidenceforimmunecheckpointtherapyinhighgradeserousovariancancer AT jcsimpson examiningtheevidenceforimmunecheckpointtherapyinhighgradeserousovariancancer AT asperry examiningtheevidenceforimmunecheckpointtherapyinhighgradeserousovariancancer AT jlysaght examiningtheevidenceforimmunecheckpointtherapyinhighgradeserousovariancancer |